

REFERENCES SUPPORTING COVID-19 BOTANICAL AND NUTRCEUTICAL RECOMMENDATIONS FOR PATIENTS

1. Hotchkiss RS, Opal SM. Activating immunity to fight a foe – a new path. *N Engl J Med.* 2020;382(13):1270-1272. doi:[10.1056/NEJMcibr1917242](https://doi.org/10.1056/NEJMcibr1917242)
2. Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents.* 2020;34(2):1. doi:[10.23812/CONTI-E](https://doi.org/10.23812/CONTI-E)
3. Ding S, Xu S, Ma Y, Liu G, Jang H, Fang J. Modulatory mechanisms of the NLRP3 inflammasomes in diabetes. *Biomolecules.* 2019;9(12):E850. doi:[10.3390/biom9120850](https://doi.org/10.3390/biom9120850)
4. Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. *Front Microbiol.* 2019;10:50. doi:[10.3389/fmicb.2019.00050](https://doi.org/10.3389/fmicb.2019.00050)
5. T?zsér J, Benk? S. Natural compounds as regulators of NLRP3 inflammasome-mediated IL-1? production. *Mediators Inflamm.* 2016;2016:5460302. doi:[10.1155/2016/5460302](https://doi.org/10.1155/2016/5460302)
6. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet.* 2020;395(10229):1033-1034. doi:[10.1016/S0140-6736\(20\)30628-0](https://doi.org/10.1016/S0140-6736(20)30628-0)
7. Adem S, Eyupoglu V, Sarfraz I, Rasul A, Ali M. Identification of potent COVID-19 main protease (Mpro) inhibitors from natural polyphenols: an in silico strategy unveils a hope against CORONA. *Preprints.* Published online March 23, 2020. doi:[10.20944/preprints202003.0333.v1](https://doi.org/10.20944/preprints202003.0333.v1)
8. Dostal Z, Modriansky M. The effect of quercetin on microRNA expression: a critical review. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.* 2019;163(2):95-106. doi:[10.5507/bp.2019.030](https://doi.org/10.5507/bp.2019.030)

9. Wu W, Li R, Li X, et al. Quercetin as an antiviral agent inhibits influenza A virus (IAV) entry. *Viruses*. 2015;8(1):E6. doi:[10.3390/v8010006](https://doi.org/10.3390/v8010006)
10. Kinker B, Comstock AT, Sajjan US. Quercetin: a promising treatment for the common cold. *J Anc Dis Prev Rem*. 2014;2:2:1000111. doi:[10.4172/2329-8731.1000111](https://doi.org/10.4172/2329-8731.1000111)
11. Somerville VS, Braakhuis AJ, Hopkins WG. Effect of flavonoids on upper respiratory tract infections and immune function: a systematic review and meta-analysis. *Adv Nutr*. 2016;7(3):488-497. doi:[10.3945/an.115.010538](https://doi.org/10.3945/an.115.010538)
12. Qiu X, Kroeker A, He S, et al. Prophylactic efficacy of quercetin 3-O-D-glucoside against Ebola virus infection. *Antimicrob Agents Chemother*. 2016;60(9):5182-5188. doi:[10.1128/AAC.00307-16](https://doi.org/10.1128/AAC.00307-16)
13. Wong G, He S, Siragam V, et al. Antiviral activity of quercetin-3-O-D-glucoside against Zika virus infection. *Virol Sin*. 2017;32(6):545-547. doi:[10.1007/s12250-017-4057-9](https://doi.org/10.1007/s12250-017-4057-9)
14. Yi YS. Regulatory roles of flavonoids on inflammasome activation during inflammatory responses. *Mol Nutr Food Res*. 2018;62(13):e1800147. doi:[10.1002/mnfr.201800147](https://doi.org/10.1002/mnfr.201800147)
15. Sun Y, Liu W, Zhang H, et al. Curcumin prevents osteoarthritis by inhibiting the activation of inflammasome NLRP3. *J Interferon Cytokine Res*. 2017;37(10):449-455. doi:[10.1089/jir.2017.0069](https://doi.org/10.1089/jir.2017.0069)
16. Andres S, Pevny S, Ziegenhagen R, et al. Safety aspects of the use of quercetin as a dietary supplement. *Mol Nutr Food Res*. 2018;62(1). doi:[10.1002/mnfr.201700447](https://doi.org/10.1002/mnfr.201700447)
17. O?arowski M, Miko?ajczak P?, Kujawski R, et al. Pharmacological effect of quercetin in hypertension and its potential application in pregnancy-induced hypertension: review of *in vitro*, *in vivo*, and clinical studies. *Evid Based Complement Alternat Med*. 2018;2018:7421489. doi:[10.1155/2018/7421489](https://doi.org/10.1155/2018/7421489)
18. Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S. Potential inhibitor of COVID-19 main protease (M^{pro}) from several medicinal plant compounds by molecular

docking study. *Preprints*. Published online March 13, 2020.

doi:[10.20944/preprints202003.0226.v1](https://doi.org/10.20944/preprints202003.0226.v1)

19. Yin H, Guo Q, Li X, et al. Curcumin suppresses IL-1 β secretion and prevents inflammation through inhibition of the NLRP3 inflammasome. *J Immunol*. 2018;200(8):2835-2846. doi:[10.4049/jimmunol.1701495](https://doi.org/10.4049/jimmunol.1701495)
20. Gong Z, Zhao S, Zhou J, et al. Curcumin alleviates DSS-induced colitis via inhibiting NLRP3 inflammasome activation and IL-1 β production. *Mol Immunol*. 2018;104:11-19. doi:[10.1016/j.molimm.2018.09.004](https://doi.org/10.1016/j.molimm.2018.09.004)
21. Zhao J, Wang J, Zhou M, Li M, Li M, Tan H. Curcumin attenuates murine lupus via inhibiting NLRP3 inflammasome. *Int Immunopharmacol*. 2019;69:213-216. doi:[10.1016/j.intimp.2019.01.046](https://doi.org/10.1016/j.intimp.2019.01.046)
22. Kunnumakkara AB, Bordoloi D, Padmavathi G, et al. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. *Br J Pharmacol*. 2017;174(11):1325-1348. doi:[10.1111/bph.13621](https://doi.org/10.1111/bph.13621)
23. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (*Curcuma longa*). *J Altern Complement Med*. 2003;9(1):161-168. doi:[10.1089/107555303321223035](https://doi.org/10.1089/107555303321223035)
24. Ng QX, Koh SSH, Chan HW, Ho CYX. Clinical use of curcumin in depression: a meta-analysis. *J Am Med Dir Assoc*. 2017;18(6):503-508. doi:[10.1016/j.jamda.2016.12.071](https://doi.org/10.1016/j.jamda.2016.12.071)
25. Ng QX, Soh AYS, Loke W, Venkatanarayanan N, Lim DY, Yeo WS. A meta-analysis of the clinical use of curcumin for irritable bowel syndrome (IBS). *J Clin Med*. 2018;7(10):E298. doi:[10.3390/jcm7100298](https://doi.org/10.3390/jcm7100298)
26. Bahramsoltani R, Rahimi R, Farzaei MH. Pharmacokinetic interactions of curcuminoids with conventional drugs: a review. *J Ethnopharmacol*. 2017;209:1-12. doi:[10.1016/j.jep.2017.07.022](https://doi.org/10.1016/j.jep.2017.07.022)

27. Xu J, Qiu JC, Ji X, et al. Potential pharmacokinetic herb-drug interactions: have we overlooked the importance of human carboxylesterases 1 and 2? *Curr Drug Metab.* 2019;20(2):130-137. doi:[10.2174/1389200219666180330124050](https://doi.org/10.2174/1389200219666180330124050)
28. Matsumoto K, Yamada H, Takuma N, Niino H, Sagesaka YM. Effects of green tea catechins and theanine on preventing influenza infection among healthcare workers: a randomized controlled trial. *BMC Complement Altern Med.* 2011;11:15. doi:[10.1186/1472-6882-11-15](https://doi.org/10.1186/1472-6882-11-15)
29. Lee HE, Yang G, Park YB, et al. Epigallocatechin-3-gallate prevents acute gout by suppressing NLRP3 inflammasome activation and mitochondrial DNA synthesis. *Molecules.* 2019;24(11):E2138. doi:[10.3390/molecules24112138](https://doi.org/10.3390/molecules24112138)
30. Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises? *Int J Mol Sci.* 2011;12(9):5592-5603. doi:[10.3390/ijms12095592](https://doi.org/10.3390/ijms12095592)
31. Chow HH, Cai Y, Hakim IA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. *Clin Cancer Res.* 2003;9(9):3312-3319.
32. Isomura T, Suzuki S, Origasa H, et al. Liver-related safety assessment of green tea extracts in humans: a systematic review of randomized controlled trials [published correction appears in *Eur J Clin Nutr.* 2016;70(11):1221-1229]. *Eur J Clin Nutr.* 2016;70(11):1340. doi:[10.1038/ejcn.2016.78](https://doi.org/10.1038/ejcn.2016.78)
33. Sarma DN, Barrett ML, Chavez ML, et al. Safety of green tea extracts: a systematic review by the US Pharmacopeia. *Drug Saf.* 2008;31(6):469-484. doi:[10.2165/00002018-200831060-00003](https://doi.org/10.2165/00002018-200831060-00003)
34. Oketch-Rabah HA, Roe AL, Rider CV, et al. United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. *Toxicol Rep.* 2020;7:386-402. doi:[10.1016/j.toxrep.2020.02.008](https://doi.org/10.1016/j.toxrep.2020.02.008)
35. Younes M, Aggett P, Aguilar F, et al. Scientific opinion on the safety of green tea catechins. *EFSA J.* 2018;16(4):e05239. doi:[10.2903/j.efsa.2018.5239](https://doi.org/10.2903/j.efsa.2018.5239)

36. McCarty MF, DiNicolantonio JJ. Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus. *Prog Cardiovasc Dis*. Published online February 12, 2020. doi:[10.1016/j.pcad.2020.02.007](https://doi.org/10.1016/j.pcad.2020.02.007)
37. Mokhtari V, Afsharian P, Shahhoseini M, Kalantar SM, Moini A. A review on various uses of N-acetyl cysteine. *Cell J*. 2017;19(1):11-17. doi:[10.22074/cellj.2016.4872](https://doi.org/10.22074/cellj.2016.4872)
38. Bauer IE, Green C, Colpo GD, et al. A double-blind, randomized, placebo-controlled study of aspirin and N-acetylcysteine as adjunctive treatments for bipolar depression. *J Clin Psychiatry*. 2018;80(1):18m12200. doi:[10.4088/JCP.18m12200](https://doi.org/10.4088/JCP.18m12200)
39. Berk M, Turner A, Malhi GS, et al. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo [published correction appears in *BMC Med*. 2019;17(1):35]. *BMC Med*. 2019;17(1):18. doi:[10.1186/s12916-019-1257-1](https://doi.org/10.1186/s12916-019-1257-1)
40. Clark RSB, Empey PE, Bay?r H, et al. Phase I randomized clinical trial of N-acetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children. *PLoS One*. 2017;12(7):e0180280. doi:[10.1371/journal.pone.0180280](https://doi.org/10.1371/journal.pone.0180280)
41. Bhatti J, Nascimento B, Akhtar U, et al. Systematic review of human and animal studies examining the efficacy and safety of N-acetylcysteine (NAC) and N-acetylcysteine amide (NACA) in traumatic brain injury: impact on neurofunctional outcome and biomarkers of oxidative stress and inflammation. *Front Neurol*. 2018;8:744. doi:[10.3389/fneur.2017.00744](https://doi.org/10.3389/fneur.2017.00744)
42. Brisdelli F, D'Andrea G, Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. *Curr Drug Metab*. 2009;10(6):530-546. doi:[10.2174/138920009789375423](https://doi.org/10.2174/138920009789375423)
43. Lin SC, Ho CT, Chuo WH, Li S, Wang TT, Lin CC. Effective inhibition of MERS-CoV infection by resveratrol. *BMC Infect Dis*. 2017;17(1):144. doi:[10.1186/s12879-017-2253-](https://doi.org/10.1186/s12879-017-2253-8)

44. Palamara AT, Nencioni L, Aquilano K, et al. Inhibition of influenza A virus replication by resveratrol. *J Infect Dis*. 2005;191(10):1719-1729. doi:[10.1086/429694](https://doi.org/10.1086/429694)
45. Euba B, López-López N, Rodríguez-Arce I, et al. Resveratrol therapeutics combines both antimicrobial and immunomodulatory properties against respiratory infection by nontypeable *Haemophilus influenzae*. *Sci Rep*. 2017;7(1):12860. doi:[10.1038/s41598-017-13034-7](https://doi.org/10.1038/s41598-017-13034-7)
46. Mendes da Silva D, Gross LA, Neto EPG, Lessey BA, Savaris RF. The use of resveratrol as an adjuvant treatment of pain in endometriosis: a randomized clinical trial. *J Endocr Soc*. 2017;1(4):359-369. doi:[10.1210/js.2017-00053](https://doi.org/10.1210/js.2017-00053)
47. Zhu CW, Grossman H, Neugroschl J, et al. A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: a pilot study. *Alzheimers Dement (N Y)*. 2018;4:609-616. doi:[10.1016/j.trci.2018.09.009](https://doi.org/10.1016/j.trci.2018.09.009)
48. Roberts VH, Pound LD, Thorn SR, et al. Beneficial and cautionary outcomes of resveratrol supplementation in pregnant nonhuman primates. *FASEB J*. 2014;28(6):2466-2477. doi:[10.1096/fj.13-245472](https://doi.org/10.1096/fj.13-245472)
49. Klink JC, Tewari AK, Masko EM, et al. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. *Prostate*. 2013;73(7):754-762. doi:[10.1002/pros.22619](https://doi.org/10.1002/pros.22619)
50. Shaito A, Posadino AM, Younes N, et al. Potential adverse effects of resveratrol: a literature review. *Int J Mol Sci*. 2020;21(6):E2084. doi:[10.3390/ijms21062084](https://doi.org/10.3390/ijms21062084)
51. Salehi B, Mishra AP, Nigam M, et al. Resveratrol: a double-edged sword in health benefits. *Biomedicines*. 2018;6(3):E91. doi:[10.3390/biomedicines6030091](https://doi.org/10.3390/biomedicines6030091)
52. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. *Ann N Y Acad Sci*. 2011;1215:161-169. doi:[10.1111/j.1749-6632.2010.05853.x](https://doi.org/10.1111/j.1749-6632.2010.05853.x)

53. Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF. Herb-drug interactions: challenges and opportunities for improved predictions. *Drug Metab Dispos.* 2014;42(3):301-317. doi:[10.1124/dmd.113.055236](https://doi.org/10.1124/dmd.113.055236)
54. Mawson AR. Role of fat-soluble vitamins A and D in the pathogenesis of influenza: a new perspective. 2013;2013:246737. *Int Sch Res Notices.* doi:[10.5402/2013/246737](https://doi.org/10.5402/2013/246737)
55. Martineau AR, Jolliffe DA, Greenberg L, et al. Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis. *Health Technol Assess.* 2019;23(2):1-44. doi:[10.3310/hta23020](https://doi.org/10.3310/hta23020)
56. Zhou J, Du J, Huang L, Wang Y, Shi Y, Lin H. Preventive effects of vitamin D on seasonal influenza A in infants: multicenter, randomized, open, controlled clinical trial. *Pediatr Infect Dis J.* 2018;37(8):749-754. doi:[10.1097/INF.0000000000001890](https://doi.org/10.1097/INF.0000000000001890)
57. Tzilas V, Bouros E, Barbayianni I, et al. Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis. *Pulm Pharmacol Ther.* 2019;55:17-24. doi:[10.1016/j.pupt.2019.01.003](https://doi.org/10.1016/j.pupt.2019.01.003)
58. Ricca C, Aillon A, Viano M, Bergandi L, Aldieri E, Silvagno F. Vitamin D inhibits the epithelial-mesenchymal transition by a negative feedback regulation of TGF- β activity. *J Steroid Biochem Mol Biol.* 2019;187:97-105. doi:[10.1016/j.jsbmb.2018.11.006](https://doi.org/10.1016/j.jsbmb.2018.11.006)
59. Fischer KD, Agrawal DK. Vitamin D regulating TGF- β induced epithelial-mesenchymal transition [published correction appears in *Respir Res.* 2015;16:139]. *Respir Res.* 2014;15:146. doi:[10.1186/s12931-014-0146-6](https://doi.org/10.1186/s12931-014-0146-6)
60. Schrumpf JA, Ninaber DK, van der Does AM, Hiemstra PS. TGF- β 1 impairs vitamin D-induced and constitutive airway epithelial host defense mechanisms. *J Innate Immun.* 2020;12(1):74-89. doi:[10.1159/000497415](https://doi.org/10.1159/000497415)
61. Liu RM, Gaston Pravia KA. Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. *Free Radic Biol Med.* 2010;48(1):1-15. doi:[10.1016/j.freeradbiomed.2009.09.026](https://doi.org/10.1016/j.freeradbiomed.2009.09.026)

62. Lu L, Lu Q, Chen W, Li J, Li C, Zheng Z. Vitamin D₃ protects against diabetic retinopathy by inhibiting high-glucose-induced activation of the ROS/TXNIP/NLRP3 inflammasome pathway. *J Diabetes Res*. 2018;2018:8193523. doi:[10.1155/2018/8193523](https://doi.org/10.1155/2018/8193523)
63. Rao Z, Chen X, Wu J, et al. Vitamin D receptor inhibits NLRP3 activation by impeding its BRCC3-mediated deubiquitination. *Front Immunol*. 2019;10:2783. doi:[10.3389/fimmu.2019.02783](https://doi.org/10.3389/fimmu.2019.02783)
64. Hewison M. Vitamin D and immune function: an overview. *Proc Nutr Soc*. 2012;71(1):50-61. doi:[10.1017/S0029665111001650](https://doi.org/10.1017/S0029665111001650)
65. Fitch N, Becker AB, HayGlass KT. Vitamin D [1,25(OH)₂D₃] differentially regulates human innate cytokine responses to bacterial versus viral pattern recognition receptor stimuli. *J Immunol*. 2016;196(7):2965-2972. doi:[10.4049/jimmunol.1500460](https://doi.org/10.4049/jimmunol.1500460)
66. Zdrenghea MT, Makrinioti H, Bagacean C, Bush A, Johnston SL, Stanciu LA. Vitamin D modulation of innate immune responses to respiratory viral infections. *Rev Med Virol*. 2017;27(1). doi:[10.1002/rmv.1909](https://doi.org/10.1002/rmv.1909)
67. Verway M, Bouttier M, Wang TT, et al. Vitamin D induces interleukin-1 β expression: paracrine macrophage epithelial signaling controls *M. tuberculosis* infection. *PLoS Pathog*. 2013;9(6):e1003407. doi:[10.1371/journal.ppat.1003407](https://doi.org/10.1371/journal.ppat.1003407)
68. Tulk SE, Liao KC, Muruve DA, Li Y, Beck PL, MacDonald JA. Vitamin D₃ metabolites enhance the NLRP3-dependent secretion of IL-1 β from human THP-1 monocytic cells. *J Cell Biochem*. 2015;116(5):711-720. doi:[10.1002/jcb.24985](https://doi.org/10.1002/jcb.24985)
69. Lee MT, Kattan M, Fennoy I, et al. Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease. *Blood Adv*. 2018;2(9):969-978. doi:[10.1182/bloodadvances.2017013979](https://doi.org/10.1182/bloodadvances.2017013979)
70. Autier P, Mullie P, Macacu A, et al. Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomised trials. *Lancet Diabetes Endocrinol*. 2017;5(12):986-1004. doi:[10.1016/S2213-8587\(17\)30357-1](https://doi.org/10.1016/S2213-8587(17)30357-1)

71. Sluyter JD, Camargo CA, Waayer D, et al. Effect of monthly, high-dose, long-term vitamin D on lung function: a randomized controlled trial. *Nutrients*. 2017;9(12):E1353. doi:[10.3390/nu9121353](https://doi.org/10.3390/nu9121353)
72. Scragg R. The vitamin D assessment (ViDA) study – design and main findings. *J Steroid Biochem Mol Biol*. 2020;198:105562. doi:[10.1016/j.jsbmb.2019.105562](https://doi.org/10.1016/j.jsbmb.2019.105562)
73. Turin A, Bax JJ, Doukas D, et al. Interactions among vitamin D, atrial fibrillation, and the renin-angiotensin-aldosterone system. *Am J Cardiol*. 2018;122(5):780-784. doi:[10.1016/j.amjcard.2018.05.013](https://doi.org/10.1016/j.amjcard.2018.05.013)
74. Zaheer S, Taquechel K, Brown JM, Adler GK, Williams JS, Vaidya A. A randomized intervention study to evaluate the effect of calcitriol therapy on the renin-angiotensin system in diabetes. *J Renin Angiotensin Aldosterone Syst*. 2018;19(1):1470320317754178. doi:[10.1177/1470320317754178](https://doi.org/10.1177/1470320317754178)
75. Cremer A, Tambosco C, Corcuff JB, et al. Investigating the association of vitamin D with blood pressure and the renin-angiotensin-aldosterone system in hypertensive subjects: a cross-sectional prospective study. *J Hum Hypertens*. 2018;32(2):114-121. doi:[10.1038/s41371-017-0005-2](https://doi.org/10.1038/s41371-017-0005-2)
76. Zittermann A, Ernst JB, Prokop S, et al. Effects of vitamin D supplementation on renin and aldosterone concentrations in patients with advanced heart failure: the EVITA trial. *Int J Endocrinol*. 2018;2018:5015417. doi:[10.1155/2018/5015417](https://doi.org/10.1155/2018/5015417)
77. Yang P, Gu H, Zhao Z, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. *Sci Rep*. 2014;4:7027. doi:[10.1038/srep07027](https://doi.org/10.1038/srep07027)
78. Xu J, Yang J, Chen J, Luo Q, Zhang Q, Zhang H. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. *Mol Med Rep*. 2017;16(5):7432-7438. doi:[10.3892/mmr.2017.7546](https://doi.org/10.3892/mmr.2017.7546)

79. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *JAMA*. 2010;303(18):1815-1822. doi:[10.1001/jama.2010.594](https://doi.org/10.1001/jama.2010.594)
80. Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, et al. Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. *JAMA Intern Med*. 2016;176(2):175-183. doi:[10.1001/jamainternmed.2015.7148](https://doi.org/10.1001/jamainternmed.2015.7148)
81. Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. *Clin Pharmacol Ther*. 2009;85(2):198-203. doi:[10.1038/clpt.2008.165](https://doi.org/10.1038/clpt.2008.165)
82. Žofková I. Hypercalcemia. Pathophysiological aspects. *Physiol Res*. 2016;65(1):1-10. doi:[10.33549/physiolres.933059](https://doi.org/10.33549/physiolres.933059)
83. Favero G, Franceschetti L, Bonomini F, Rodella LF, Rezzani R. Melatonin as an anti-inflammatory agent modulating inflammasome activation. *Int J Endocrinol*. 2017;2017:1835195. doi:[10.1155/2017/1835195](https://doi.org/10.1155/2017/1835195)
84. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discov*. 2020;6:14. doi:[10.1038/s41421-020-0153-3](https://doi.org/10.1038/s41421-020-0153-3)
85. Zhang R, Wang X, Ni L, et al. COVID-19: melatonin as a potential adjuvant treatment. *Life Sci*. Published online March 23, 2020. doi:[10.1016/j.lfs.2020.117583](https://doi.org/10.1016/j.lfs.2020.117583)
86. Foley HM, Steel AE. Adverse events associated with oral administration of melatonin: a critical systematic review of clinical evidence. *Complement Ther Med*. 2019;42:65-81. doi:[10.1016/j.ctim.2018.11.003](https://doi.org/10.1016/j.ctim.2018.11.003)
87. Andersen LP, Gögenur I, Rosenberg J, Reiter RJ. The safety of melatonin in humans. *Clin Drug Investig*. 2016;36(3):169-175. doi:[10.1007/s40261-015-0368-5](https://doi.org/10.1007/s40261-015-0368-5)
88. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. *Cochrane Database Syst Rev*. 2002;2:CD001520. doi:[10.1002/14651858.CD001520](https://doi.org/10.1002/14651858.CD001520)

89. Leite Pacheco R, de Oliveira Cruz Latorraca C, Adriano Leal Freitas da Costa A, Luiza Cabrera Martimbianco A, Vianna Pachito D, Riera R. Melatonin for preventing primary headache: a systematic review. *Int J Clin Pract*. 2018;72(7):e13203. doi:[10.1111/ijcp.13203](https://doi.org/10.1111/ijcp.13203)
90. Abdelgadir IS, Gordon MA, Akobeng AK. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis. *Arch Dis Child*. 2018;103(12):1155-1162. doi:[10.1136/archdischild-2017-314181](https://doi.org/10.1136/archdischild-2017-314181)
91. Besag FMC, Vasey MJ, Lao KSJ, Wong ICK. Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: a systematic review. *CNS Drugs*. 2019;33(12):1167-1186. doi:[10.1007/s40263-019-00680-w](https://doi.org/10.1007/s40263-019-00680-w)
92. Harpsøe NG, Andersen LP, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. *Eur J Clin Pharmacol*. 2015;71(8):901-909. doi:[10.1007/s00228-015-1873-4](https://doi.org/10.1007/s00228-015-1873-4)
93. Wirtz PH, Spillmann M, Bärtschi C, Ehlert U, von Känel R. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. *J Pineal Res*. 2008;44(2):127-133. doi:[10.1111/j.1600-079X.2007.00499.x](https://doi.org/10.1111/j.1600-079X.2007.00499.x)
94. McGlashan EM, Nandam LS, Vidafar P, Mansfield DR, Rajaratnam SMW, Cain SW. The SSRI citalopram increases the sensitivity of the human circadian system to light in an acute dose. *Psychopharmacology (Berl)*. 2018;235(11):3201-3209. doi:[10.1007/s00213-018-5019-0](https://doi.org/10.1007/s00213-018-5019-0)
95. Huang Z, Liu Y, Qi G, Brand D, Zheng SG. Role of vitamin A in the immune system. *J Clin Med*. 2018;7(9):E258. doi:[10.3390/jcm7090258](https://doi.org/10.3390/jcm7090258)
96. Cui D, Moldoveanu Z, Stephensen CB. High-level dietary vitamin A enhances T-helper type 2 cytokine production and secretory immunoglobulin A response to influenza A virus infection in BALB/c mice. *J Nutr*. 2000;130(5):1132-1139. doi:[10.1093/jn/130.5.1132](https://doi.org/10.1093/jn/130.5.1132)

97. Rothman KJ, Moore LL, Singer MR, Nguyen US, Mannino S, Milunsky A. Teratogenicity of high vitamin A intake. *N Engl J Med*. 1995;333(21):1369-1373. doi:[10.1056/NEJM199511233332101](https://doi.org/10.1056/NEJM199511233332101)
98. Bartlett H, Eperjesi F. Possible contraindications and adverse reactions associated with the use of ocular nutritional supplements. *Ophthalmic Physiol Opt*. 2005;25(3):179-194. doi:[10.1111/j.1475-1313.2005.00294.x](https://doi.org/10.1111/j.1475-1313.2005.00294.x)
99. Bendich A, Langseth L. Safety of vitamin A. *Am J Clin Nutr*. 1989;49(2):358-371. doi:[10.1093/ajcn/49.2.358](https://doi.org/10.1093/ajcn/49.2.358)
100. Cruz S, da Cruz SP, Ramalho A. Impact of vitamin A supplementation on pregnant women and on women who have just given birth: a systematic review. *J Am Coll Nutr*. 2018;37(3):243-250. doi:[10.1080/07315724.2017.1364182](https://doi.org/10.1080/07315724.2017.1364182)
101. Oliveira JM, Allert R, East CE. Vitamin A supplementation for postpartum women. *Cochrane Database Syst Rev*. 2016;3:CD005944. doi:[10.1002/14651858.CD005944.pub3](https://doi.org/10.1002/14651858.CD005944.pub3)
102. García-Cortés M, Robles-Díaz M, Ortega-Alonso A, Medina-Caliz I, Andrade RJ. Hepatotoxicity by dietary supplements: a tabular listing and clinical characteristics. *Int J Mol Sci*. 2016;17(4):537. doi:[10.3390/ijms17040537](https://doi.org/10.3390/ijms17040537)
103. Porter RS, Bode RF. A review of the antiviral properties of black elder (*Sambucus nigra* L.) products. *Phytother Res*. 2017;31(4):533-554. doi:[10.1002/ptr.5782](https://doi.org/10.1002/ptr.5782)
104. Chen C, Zuckerman DM, Brantley S, et al. *Sambucus nigra* extracts inhibit infectious bronchitis virus at an early point during replication. *BMC Vet Res*. 2014;10:24. doi:[10.1186/1746-6148-10-24](https://doi.org/10.1186/1746-6148-10-24)
105. Barak V, Halperin T, Kalickman I. The effect of Sambucol, a black elderberry-based, natural product, on the production of human cytokines: I. Inflammatory cytokines. *Eur Cytokine Netw*. 2001;12(2):290-296.

106. Barak V, Birkenfeld S, Halperin T, Kalickman I. The effect of herbal remedies on the production of human inflammatory and anti-inflammatory cytokines. *Isr Med Assoc J*. 2002;4(11 Suppl):919-922.
107. Ulbricht C, Basch E, Cheung L, et al. An evidence-based systematic review of elderberry and elderflower (*Sambucus nigra*) by the Natural Standard Research Collaboration. *J Diet Suppl*. 2014;11(1):80-120. doi:[10.3109/19390211.2013.859852](https://doi.org/10.3109/19390211.2013.859852)
108. Frank T, Janssen M, Netzet G, Christian B, Bitsch I, Netzel M. Absorption and excretion of elderberry (*Sambucus nigra* L.) anthocyanins in healthy humans. *Methods Find Exp Clin Pharmacol*. 2007;29(8):525-533. doi:[10.1358/mf.2007.29.8.1116309](https://doi.org/10.1358/mf.2007.29.8.1116309)
109. Badescu M, Badulescu O, Badescu L, Ciocoiu M. Effects of *Sambucus nigra* and *Aronia melanocarpa* extracts on immune system disorders within diabetes mellitus. *Pharm Biol*. 2015;53(4):533-539. doi:[10.3109/13880209.2014.931441](https://doi.org/10.3109/13880209.2014.931441)
110. Curtis PJ, Kroon PA, Hollands WJ, et al. Cardiovascular disease risk biomarkers and liver and kidney function are not altered in postmenopausal women after ingesting an elderberry extract rich in anthocyanins for 12 weeks. *J Nutr*. 2009;139(12):2266-2271. doi:[10.3945/jn.109.113126](https://doi.org/10.3945/jn.109.113126)
111. Fallah AA, Sarmast E, Fatehi P, Jafari T. Impact of dietary anthocyanins on systemic and vascular inflammation: systematic review and meta-analysis on randomised clinical trials. *Food Chem Toxicol*. 2020;135:110922. doi:[10.1016/j.fct.2019.110922](https://doi.org/10.1016/j.fct.2019.110922)
112. Li S, Wu B, Fu W, Reddivari L. The anti-inflammatory effects of dietary anthocyanins against ulcerative colitis. *Int J Mol Sci*. 2019;20(10):E2588. doi:[10.3390/ijms20102588](https://doi.org/10.3390/ijms20102588)
113. Elderberry for influenza. *Med Lett Drugs Ther*. 2019;61(1566):32. [<https://secure.medicalletter.org/w1566f>]
114. Hawkins J, Baker C, Cherry L, Dunne E. Black elderberry (*Sambucus nigra*) supplementation effectively treats upper respiratory symptoms: a meta-analysis of

- randomized, controlled clinical trials. *Complement Ther Med*. 2019;42:361-365.
doi:[10.1016/j.ctim.2018.12.004](https://doi.org/10.1016/j.ctim.2018.12.004)
115. Keppel Hesselink JM, de Boer T, Witkamp RF. Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold. *Int J Inflam*. 2013;2013:151028. doi:[10.1155/2013/151028](https://doi.org/10.1155/2013/151028)
116. Cordaro M, Cuzzocrea S, Crupi R. An update of palmitoylethanolamide and luteolin effects in preclinical and clinical studies of neuroinflammatory events. *Antioxidants (Basel)*. 2020;9(3):E216. doi:[10.3390/antiox9030216](https://doi.org/10.3390/antiox9030216)
117. Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. *Am J Hosp Palliat Care*. 2019;36(12):1134-1154. doi:[10.1177/1049909119850807](https://doi.org/10.1177/1049909119850807)
118. Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. *Br J Clin Pharmacol*. 2016;82(4):932-942. doi:[10.1111/bcp.13020](https://doi.org/10.1111/bcp.13020)
119. Natural Medicines Database. Palmitoylethanolamide (PEA). Accessed March 30, 2020. <https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=1596>
120. Fischer Walker C, Black RE. Zinc and the risk for infectious disease. *Annu Rev Nutr*. 2004;24:255-275. doi:10.1146/annurev.nutr.23.011702.073054
121. Fraker PJ, King LE, Laakko T, Vollmer TL. The dynamic link between the integrity of the immune system and zinc status. *J Nutr*. 2000;130(5S Suppl):1399S-1406S. doi:10.1093/jn/130.5.1399S
122. Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. *Am J Clin Nutr*. 1998;68(2 Suppl):447S-463S. doi:10.1093/ajcn/68.2.447S
123. Gao H, Dai W, Zhao L, Min J, Wang F. The role of zinc and zinc homeostasis in macrophage function. *J Immunol Res*. 2018;2018:6872621. doi:10.1155/2018/6872621

124. Meydani SN, Barnett JB, Dallal GE, et al. Serum zinc and pneumonia in nursing home elderly. *Am J Clin Nutr.* 2007;86(4):1167-1173. doi:10.1093/ajcn/86.4.1167
125. Barnett JB, Dao MC, Hamer DH, et al. Effect of zinc supplementation on serum zinc concentration and T cell proliferation in nursing home elderly: a randomized, double-blind, placebo-controlled trial. *Am J Clin Nutr.* 2016;103(3):942-951. doi:10.3945/ajcn.115.115188
126. Maares M, Haase H. Zinc and immunity: an essential interrelation. *Arch Biochem Biophys.* 2016;611:58-65. doi:10.1016/j.abb.2016.03.022
127. te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog.* 2010;6(11):e1001176. doi:10.1371/journal.ppat.1001176
128. King JC, Brown KH, Gibson RS, et al. Biomarkers of nutrition for development (BOND)—zinc review. *J Nutr.* 2015;146(4):858S-885S. doi:10.3945/jn.115.220079